Comparative activities of the triterpene saponin Maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in Hamsters

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2056-2060

  Maes, Louis ^a   Germonprez, Nils ^c   Quirijnen, Ludo ^b   Van Puyvelde, Luc ^c   Cos, Paul ^a   Vanden Berghe, Dirk ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b TIBOTEC BVBA   (Belgium)

^c Natl Ctr Nat Sci/Technol   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; MAESA BALANSAE EXTRACT; MAESABALIDE III; PX 6518; SAPONIN; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HAMSTER; LEISHMANIA DONOVANI; LEISHMANIASIS; LIVER; MAESA BALANSAE; MALE; NONHUMAN; PLANT; PRIORITY JOURNAL; SPLEEN; TREATMENT OUTCOME; VALIDATION PROCESS; VIET NAM;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; BODY WEIGHT; CRICETINAE; DRUG CARRIERS; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; LIVER; MALE; PARASITE EGG COUNT; SAPONINS;

EID: 2542446356     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2056-2060.2004     Document Type: Article

References (20)

1. Agrawal, A. K., A. Agrawal, A. Pal, P. Y. Guru, and C. M. Gupta. 2002. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J. Drug Target. 10:41-45.
2. Berman, J. D., W. L. Hanson, W. L. Chapman, C. R. Alving, and G. Lopez-Berestein. 1986. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 30:847-851.
3. Bradley, D. J. 1977. Regulation of Leishmania populations within the host. II. Genetic control of acute susceptibility of mice to Leishmania donovani infection. Clin. Exp. Immunol. 30:130-140.
4. Bryceson, A. 2001. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6:928-934.
5. Chiu, Y. Y. 2000. Guidance for industry. Botanical drug products, draft guidance. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md.
6. Committee for Proprietary Medicinal Products-Committee for Veterinary Medicinal Products. 2001. Note for guidance on specifications: test procedures and acceptance criteria for herbal drugs, herbal drug preparations and herbal medicinal products. EMEA/CVMP/815/00. Committee for Proprietary Medicinal Products-Committee for Veterinary Medicinal Products, London, United Kingdom.
7. Gangneux, J. P., A. Sulahian, Y. J. Garin, R. Farinotti, and F. Derouin. 1996. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother. 40:1214-1218.
8. Germonprez, N., L. Van Puyvelde, L. Maes, M. Van Tri, and N. De Kimpe. 2003. New pentacyclic triterpene saponins with strong anti-leishmanial activity from the leaves of Maesa balansae. Tetrahedron 60:219-228.
9. Guerin, P., J. P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson. 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2:494-501.
10. Maes, L., D. Vanden Berghe, N. Germonprez, L. Quirijnen, P. Cos, N. De Kimpe, and L. Van Puyvelde. 2003. In vitro and in vivo activity of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species. Antimicrob. Agents Chemother. 48:130-136.
11. Melby, P. C., B. Chandrasekar, W. Zhao, and J. E. Coe. 2001. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166:1912-1920.
12. Mullen, A. B., A. J. Baillie, and K. C. Carter. 1998. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42:2722-2725.
13. Mullen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
14. Murray, H. W., H. Masur, and J. S. Keithly. 1982. Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J. Immunol. 129:344-350.
15. Pecoul, B., P. Chirac, P. Trouiller, and J. Pinel. 1999. Access to essential drugs in poor countries: a lost battle? JAMA 281:361-367.
16. Requena, J. M., M. Soto, M. D. Doria, and C. Alonso. 2000. Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model. Vet. Immunol. Immunopathol. 76:269-281.
17. Stauber, L. A. 1966. Characterisation of strains of Leishmania donovani. Exp. Parasitol. 18:1-11.
18. Sundar, S., and M. Rai. 2002. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15:593-598.
19. Sundar, S. 2001. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6:849-854.
20. Yardley, V., and S. L. Croft. 2000. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13:243-248.